健康人体血小板中的氨酸- ангиотензин系统:表达但不活跃
François Panosetti1,2, François M Cuenot1, Damian S Saint Auguste1
1Laboratory of Hemodynamics and Cardiovascular Technology (LHTC), Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Platelets
|August 18, 2025
概括
人类血小板表达氨酸-血管氨系统 (RAS) 受体,但RAS不会影响血小板功能. 这表明COVID-19凝血病可能独立于血小板中的RAS途径.
科学领域:
- 心血管生物学 心血管生物学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血小板是动脉血栓形成的关键,为抗血小板药物提供治疗点.
- 氨酸- ангиотензин系统 (RAS) 与心血管功能和炎症有关.
- COVID-19与凝血病有关,其中RAS的作用尚不清楚.
研究的目的:
- 为了研究人体血小板内RAS成分的存在和功能.
- 为了探索血小板RAS在COVID-19相关的凝血病的潜在参与.
主要方法:
- 西方斑点和免疫光检测人类血小板中的RAS受体表达.
- 在实验室中用RAS和Captopril化血小板.
- 对血小板粘附,激活,聚合,ACE和ACE2活性进行检测.
主要成果:
- 人类血小板表达Mas,MrgD,ACE,ACE2,AT1和AT2受体.
- 拉斯酸没有改变血小板粘附或聚合.
- 检测到血小板ACE活性,但Captopril没有抑制;ACE2活性是无法检测的.
结论:
- 人类血小板表达RAS受体,但RAS在测试条件下不会影响血小板功能.
- 这些发现表明,血小板中的RAS信号可能不是COVID-19凝血病的重要因素.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
819
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
819
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
875
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
875
Antihypertensive Drugs: Angiotensin II Receptor Blockers
915
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
915
Hormonal Regulation
33.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.7K
Hypertension II: Pathophysiology
77
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
77
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505


